AlphaFold pioneer who won a Nobel Prize alongside Demis Hassabis leaves Google DeepMind for Anthropic - Business Insider

Demis Hassabis is becoming the chief scientist of Alphabet and chair of Google DeepMind. Google is shaking up its AI leadership, with some of the company's top experts in the field moving roles or leaving. Shares of the tech giant fell as much as 5% on the news. Demis Hassabis is shedding his CEO title at DeepMind to take on a broader AI research role at Alphabet, Google's parent company. Koray Kavukcuoglu, previously DeepMind's chief technology officer, will head the unit, reporting to Google CEO Sundar Pichai. Hassabis, one of the pioneers of modern AI, will become chief scientist of Alphabet and chair of Google DeepMind. He's been tipped by some to be the next CEO, and lately he's been meeting with global policy leaders and making grand speeches about the long-term future of this technology. Jeff Dean, a top AI researcher who's been at Google for decades, is leaving to start his own initiative, Discovery Loop, with Sanjay Ghemawat, another top tech leader at the search giant. "We have to accelerate all this work and stay focused on the AI frontier," Pichai wrote in a blog post on Wednesday.

OttawaDi Rienzo Grocery & Deli in Ottawa's Little Italy is for sale. After decades spent serving up sandwiches and pasta, the owner says it is time to step away. Owner says after 54 years in business, now is the right time to retireCBC News · Posted: Oct 23, 2026 12:05 PM EDT | Last Updated: 1 hour agoListen to this articleEstimated 2 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Di Rienzo's deli in Ottawa's Little Italy is listed for sale. (Joseph Tunney/CBC)Di Rienzo Grocery & Deli in Ottawa's Little Italy is for sale. After decades spent serving up sandwiches and pasta, the owner says it is time to step away. "We have decided that it was time, after 54 years, because otherwise you say, 'OK, we'll do it this year, we'll do it another year, we'll do it another year.' I think this is time," said owner Paolo Di Rienzo. The shop has been a fixture on Beech Street since the early 1970s, known for its widely popular sandwiches.

AtlanticNova ScotiaNew BrunswickPrince Edward Island Newfoundland and LabradorCalgaryLethbridgeKitchenerGuelphNorthern OntarioSudburyNorth BaySault Ste. MarieTimminsOttawaKingstonBrockvillePembrokeReginaYorktonSaskatoonPrince AlbertTorontoWatchWeatherPeelHamiltonDurhamYorkHaltonNiagaraQueen's ParkToronto City HallIn PicturesVancouverVancouver IslandCanadaLocal SpotlightRoyal FamilyPoliticsNanosPower PlayQuestion PeriodFederal Election 2025WorldMideast ConflictRussia-Ukraine WarWatchLatestCaptured on CameraPoliticsLifestyleConsumerHealthExplainedEntertainmentTechnologyDeception DecodedAutosEnvironmentBusinessInflationReal EstateAutos

Severe sunburn increases the risk of developing melanoma, the most serious type of skin cancer. Credit: Olga Pankova/GettyA personalized mRNA vaccine reduced the risk of skin cancer returning or the recipient dying by 42% when used alongside an immunotherapy drug, according to long-awaited results for what could become the first approved mRNA vaccine for cancer. Oncologists regard a risk reduction of 10% as substantial, says Kristen Radford, an immunotherapist at Mater Research in Brisbane. A risk reduction of more than 40% “would send many researchers over the Moon”, adds Seth Cheetham, a geneticist at the University of Queensland in Brisbane, Australia. The personalized vaccine, called intismeran, is not designed to prevent skin cancer, or melanoma, from developing in the first place, but to stop it returning in people who have already undergone surgery to remove tumours. Anticipation for the trial results has been building since August, when the vaccine’s developers — Merck, based in Rahway, New Jersey, and Moderna, which is headquartered in Cambridge, Massachusetts — announced early positive results.